article thumbnail

Innovation in immuno-oncology: Leading companies in in-vitro T-cell activation

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: In-vitro T-cell activation. Immatics is the leading patent filer in in-vitro T-cell activation.

In-Vitro 130
article thumbnail

Study: Prednisone does not improve in vitro fertilization outcomes

Medical Xpress

Among patients with recurrent implantation failure during in vitro fertilization, treatment with prednisone does not improve the live birth rate versus placebo, according to a study published in the May 2 issue of the Journal of the American Medical Association (JAMA).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In Vitro Pharmacology Working Group to address data standards

Drug Discovery World

A new In Vitro Pharmacology Working Group to accelerate regulatory submissions has been created by the Pistoia Alliance, a global advocate for greater collaboration in life sciences R&D. The post In Vitro Pharmacology Working Group to address data standards appeared first on Drug Discovery World (DDW).

article thumbnail

New EU in vitro regulations delaying access to treatments

Drug Discovery World

The In Vitro Diagnostic Regulation (IVDR) came into effect in May 2022. The number of clinical trials delayed is expected to run into the hundreds, affecting up to 42,200 patients over the next three years, according to a survey run by EFPIA. However, this process is currently complex and uncoordinated.

article thumbnail

Enanta secures FDA fast track designation for EDP-323 to treat RSV

Pharmaceutical Technology

In vitro data of EDP-323 showed a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B. Enanta Pharmaceuticals has secured the US Food and Drug Administration’s (FDA) fast track designation for EDP-323 to treat respiratory syncytial virus (RSV).

In-Vitro 276
article thumbnail

New model for cancer risk assessment of air pollution based on in vitro testing of collected environmental samples

Medical Xpress

A study by researchers at Institute of Environmental Medicine shows that in vitro new approach methodologies (NAMs) can be a useful tool to improve cancer risk assessment (CRA) strategies in the context of complex environmental mixtures as such air pollution.

article thumbnail

TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies

The Pharma Data

Findings show that guselkumab is able to dose-dependently bind to CD64+ a myeloid cells, 1 the predominant source of IL-23-driven inflammation in the gut. 2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18 th Congress of the European Crohn’s and Colitis Organization (ECCO), taking place in Copenhagen, Denmark, March 1-4.